Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.
Biopharma, medical device, and in vitro diagnostics
start-ups brought in a total of $976 million in the fourth quarter
of 2009, a whopping 88% increase from the previous quarter, and a
77% jump from Q4 2008's $551 million. Of the total Q4 09
fundraising, 66% or $640 million went to the biopharmaceutical
industry. Compared with Q3 2009, device fundraising rose by 85%
(from $113 million to $209 million) and diagnostics companies
raised 72% more (from $74 million to $127 million). ( See
Exhibit 1.)
In TheIN VIVO Blog's Second Annual Deal of the Year competition, Movetis NV's €98 million ($147 million) initial public...
